

Endogard Plus XL Tablets for Dogs

Authorised

- Praziquantel
- Febantel
- Pyrantel embonate

Product identification

Medicine name:

Endogard Plus XL Tablets for Dogs

Active substance:

Praziquantel

Febantel

Pyrantel embonate

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Praziquantel

175.00 milligram(s) / 1.00 Tablet

Febantel

525.00 milligram(s) / 1.00 Tablet

Pyrantel embonate

504.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP52AC55

Legal status of supply:

Veterinary medicinal product not subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

United Kingdom (Northern Ireland)

Package description:

Print and perforated Alu-Alu blister: 102 tablets (17 blisters with 6 tablets), in a box.
Print and perforated Alu-Alu blister: 100 tablets (10 blisters with 10 tablets), in a box.
Print and perforated Alu-Alu blister: 60 tablets (6 blisters with 10 tablets), in a box.
Print and perforated Alu-Alu blister: 60 tablets (10 blisters with 6 tablets), in a box.
Print and perforated Alu-Alu blister: 50 tablets (5 blisters with 10 tablets), in a box
Print and perforated Alu-Alu blister: 30 tablets (5 blisters with 6 tablets), in a box.
Print and perforated Alu-Alu blister: 30 tablets (3 blisters with 10 tablets), in a box.
Print and perforated Alu-Alu blister: 24 tablets (4 blisters with 6 tablets), in a box.
Print and perforated Alu-Alu blister: 12 tablets (2 blisters with 6 tablets), in a box.
Print and perforated Alu-Alu blister: 10 tablets (1 blister with 10 tablets), in a box.
Print and perforated Alu-Alu blister: 4 tablets (2 blisters with 2 tablets), in a box.
Print and perforated Alu-Alu blister: 2 tablets (1 blister with 2 tablets), in a box.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

2/06/2011

Manufacturing sites for batch release:

KRKA tovarna zdravil d.d. Novo mesto

Krka-Farma d.o.o.

Virbac

Responsible authority:

The Veterinary Medicines Directorate

Authorisation number:

Vm 01656/4018

Date of authorisation status change:

1/12/2024

Reference member state:

Ireland

Procedure number:

IE/V/0539/002

Concerned member states:

Austria Belgium Czechia Denmark Estonia Germany Greece Hungary Italy

Latvia Lithuania Netherlands Poland Portugal Slovakia Slovenia Spain

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics